Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 12/20 | 0.45 |
| ▸ | PRSS1 | P07477 | 12/20 | 0.45 |
| ▸ | PRSS2 | P07478 | 6/20 | 0.45 |
| ▸ | PRSS3 | P35030 | 6/20 | 0.45 |
| ▸ | HPN | P05981 | 2/20 | 0.45 |
| ▸ | HGFAC | Q04756 | 2/20 | 0.45 |
| ▸ | ST14 | Q9Y5Y6 | 2/20 | 0.45 |
| ▸ | TPSAB1 | Q15661 | 4/20 | 0.42 |
| ▸ | F2 | P00734 | 2/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.39 |
| ▸ | PLG | P00747 | 1/20 | 0.38 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.38 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4587626 | 0.99 | F10 (0.44) | F10PRSS1PRSS2PRSS3HPN | |
| SCHEMBL5640091 | 0.93 | PRSS1 (0.43) | F10PRSS1PRSS2PRSS3HPN | |
| SCHEMBL5641828 | 0.87 | TPSAB1 (0.44) | F10PRSS1PRSS2PRSS3HPN | |
| SCHEMBL5641859 | 0.86 | F10 (0.41) | F10PRSS1PRSS2PRSS3HPN | |
| SCHEMBL5639756 | 0.86 | BCHE (0.50) | — | |
| SCHEMBL5640706 | 0.84 | LMNA (0.50) | F10PRSS1PRSS2PRSS3HPN | |
| SCHEMBL4587696 | 0.83 | F10 (0.42) | F10PRSS1PRSS2PRSS3HPN | |
| SCHEMBL5643104 | 0.83 | BCHE (0.43) | F10KCNH2CACNA1IALDH1A1 | |
| SCHEMBL5640468 | 0.82 | F10 (0.48) | F10ALDH1A1 | |
| SCHEMBL4588119 | 0.82 | F10 (0.40) | F10PRSS1PRSS2PRSS3HPN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199149-B2 | Monocyclic and bicyclic lactams as factor Xa inhibitors | BRISTOL MYERS SQUIBB COMPANY (US) | 2007-04-03 | — | — | US | disclosed |
| US-20050107361-A1 | Monocyclic and bicyclic lactams as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMANY | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107361-A1 | Monocyclic and bicyclic lactams as factor Xa inhibitors | F2, F12, SPINT2 | F10 18/4885PRSS1 9/4885PRSS2 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.